Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatm...
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
Basel, October 18, 2024 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommend...
Here's Why Novartis (NVS) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Swiss competition authority closes Novartis probe without consequences
Switzerland's COMCO competition commission terminated an investigation against Novartis into possibly using blocking patents, without consequences, it said on Thursday.
Novartis: Value Continues To Build With Double-Digit Percentage Growth Products
Kesimpta continues to do well as a self-administered drug for the treatment of patients with relapsing multiple sclerosis; Q2 2024 sales of $799 million, which is growth of 65% YOY. Pluvicto, as a ...
Novartis: Best Performing Big Pharma Of Past 6 Months Still Looks A Solid Long-Term Bet
Novartis shares have risen over 20% in the past 6 months, making it the best-performing global pharmaceutical stock, with strong profitability and manageable debt. Despite some declining revenues f...
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.
Novartis not joining the 'frenzy' of weight loss drugs, CEO says
Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs. CEO Vas Narasimhan said the company was researching treatments that deal wi...
Novartis not joining the 'frenzy' of weight loss drugs, CEO says
Vas Narasimhan, CEO of Novartis, says the pharmaceutical company does not plan to follow competitors in entering into the weight loss drugs market.
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early br...
Basel, September 16, 2024 – In an updated analysis from the pivotal Phase III NATALEE trial, investigational Kisqali® (ribociclib) added to endocrine therapy (ET) shows a deepening benefit beyond t...
NVS or LLY: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Novartis (NVS) or Eli Lilly (LLY). But which of these two stocks presents investors with the bette...
Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study
NVS' late-stage study meets its primary endpoints, demonstrating the superiority of Leqvio monotherapy over both placebo and ezetimibe in LDL-C reduction.
Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or ...
Basel, August 28, 2024 – Novartis announced today positive topline results from twice-yearly* Leqvio® (inclisiran) in the Phase III V-MONO study, which met its primary endpoints. Leqvio monotherapy...
Siemens Healthineers to buy Novartis unit for over $223 million, FT reports
Siemens Healthineers will pay more than 200 million euros ($223.8 million) to acquire the diagnostic arm of Advanced Accelerator Applications, owned by Novartis , the Financial Times reported on Sa...
Related Companies